Background: Animal models suggest that aging negatively affects the cerebral blood flow (CBF) response to a hypotensive challenge while research with humans suggests that chronic physical activity may positively affect age-associated alterations in CBF. The extent to which chronic exercise affects the CBF responses to orthostatic stress in older subjects is unknown. Objectives: The purpose of this study was to determine the extent to which differences in age and cardiovascular fitness, reflective of differences in chronic exercise training, affect cerebral blood flow responses to severe orthostatic stress. Methods: Subjects were divided into four groups: old fit (OF; 72 ± 2 year-olds; 38.7 ± 1.6 ml·kg–1·min–1), old unfit (OU; 71 ± 1 year-olds; 27.7 ± 2.9 ml·kg–1·min–1), young fit (YF; 23 ± 0.5 year-olds; 56.1 ± 1.8 ml·kg–1·min–1) and young unfit (YU; 23 ± 1 year-olds; 41.1 ± 1.6 ml·kg–1·min–1). Fitness was quantified with maximal graded exercise testing. Middle cerebral artery blood flow velocity (CBF velocity; transcranial Doppler) responses to graded orthostatic stress (lower body negative pressure) to presyncope were assessed. Results: Orthostatic tolerance did not differ between groups (p = 0.633). The groups differed in fitness (YF >YU = OF >OU; p < 0.001) but not in either resting CBF velocity (p = 0.364) or pulsatility index (PI; p = 0.251). CBF velocity decreased below rest in the last completed stage of submaximal LBNP (p < 0.001) but did not differ between groups (p = 0.182). PI did not change with submaximal LBNP within groups. At presyncope, mean CBF velocity decreased below that of the last completed stage of LBNP in all groups (p < 0.001) while the PI increased in the young fit group only (p < 0.001). Conclusion: Marked differences in age and fitness did not affect cerebral blood flow responses to severe orthostatic stress. While severe orthostatic stress can compromise CBF velocity in all age groups, older adults appear to autoregulate CBF as well as much younger subjects.

Keywords:
Orthostatic tolerance, Aged, Cerebrovascular circulation
This content is only available via PDF.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.